BASELINE INTERLEUKIN-17A PREDICT TREATMENT RESPONSE TO TOCILIZUMAB AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS THERAPY

被引:0
|
作者
Lee, S. J. [1 ,2 ,3 ]
Yoon, M. J. [3 ]
Joo, S. H. [3 ]
Park, W. [4 ]
Park, S. H. [5 ]
Shim, S. C. [6 ]
Baek, H. J. [7 ]
Yoo, D. -H. [8 ]
Kim, H. A. [9 ]
Lee, S. K. [10 ]
Lee, Y. J. [11 ]
Park, Y. E. [12 ]
Cha, H. -S. [13 ]
Choi, I. A. [14 ]
Lee, E. Y. [1 ,2 ]
Lee, E. B. [1 ,2 ]
Song, Y. W. [1 ,2 ,3 ]
机构
[1] Seoul Natl Univ, WCU, Grad Sch Convergence Sci & Technol, Seoul, South Korea
[2] Seoul Natl Univ, Coll Med, Med Res Inst, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Div Rheumatol, Seoul 110744, South Korea
[4] Inha Univ Hosp, Div Rheumatol, Seoul, South Korea
[5] Catholic Univ Korea, Seoul St Marys Hosp, Div Rheumatol, Seoul, South Korea
[6] Eulji Univ Hosp, Div Rheumatol, Taejon, South Korea
[7] Gachon Univ, Gil Med Ctr, Div Rheumatol, Inchon, South Korea
[8] Hanyang Univ, Med Ctr, Div Rheumatol, Seoul 133791, South Korea
[9] Hallym Univ, Med Ctr, Div Rheumatol, Seoul, South Korea
[10] Yonsei Univ Hlth Syst, Div Rheumatol, Seoul, South Korea
[11] Seoul Natl Univ, Bundang Hosp, Div Rheumatol, Seoul, South Korea
[12] Pusan Natl Univ Hosp, Div Rheumatol, Pusan, South Korea
[13] Sam Sung Med Ctr, Div Rheumatol, Seoul, South Korea
[14] Chung Buk Natl Univ Hosp, Div Rheumatol, Cheongju, South Korea
关键词
D O I
10.1136/annrheumdis-2014-eular.5095
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
SAT0059
引用
收藏
页码:610 / 611
页数:2
相关论文
共 50 条
  • [41] The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology
    Landewe, Robert B. M.
    LANCET RHEUMATOLOGY, 2021, 3 (04): : 306 - 312
  • [42] Immunizations in Adults Taking Disease-Modifying Antirheumatic Drugs
    Thome, Joel
    US PHARMACIST, 2013, 38 (04) : 38 - 43
  • [43] Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Rosales Rosado, Zulema
    Leon, Leticia
    Freites Nunez, Dalifer
    Font Urgelles, Judit
    Leon Cardenas, Cynthia Milagros
    Vadillo Font, Cristina
    Rodriguez Rodriguez, Luis
    Jover Jover, Juan A.
    Abasolo Alcazar, Lydia
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [44] ADHERENCE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATIC DISEASES
    Pineda Sic, Rita Angelica
    de Jesus Hernandez-Galarza, Ivan
    Castro-Gonzalez, Marielva
    Angel Galarza-Delgado, Dionicio
    Angel Villarreal-Alarcon, Miguel
    Allan Uriarte Botello, Rodolfo
    Ilizaliturri Guerra, Octavio
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1681 - 1681
  • [45] Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs
    Combe, Bernard
    Dasgupta, Bhaskar
    Louw, Ingrid
    Pal, Sarvajeet
    Wollenhaupt, Juergen
    Zerbini, Cristiano
    Beaulieu, Andre D.
    Schulze-Koops, Hendrik
    Durez, Patrick
    Yao, Ruji
    Vastesaeger, Nathan
    Weng, Holly
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S205 - S205
  • [46] A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs
    Sherine E. Gabriel
    Douglas Coyle
    Larry W. Moreland
    PharmacoEconomics, 2001, 19 : 715 - 728
  • [47] Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs
    Marchesoni, Antonio
    Lubrano, Ennio
    Cauli, Alberto
    Ricci, Massimo
    Manara, Maria
    JOURNAL OF RHEUMATOLOGY, 2015, 42 : 61 - 64
  • [48] The Actual Role of Therapy with Traditional Disease-modifying Antirheumatic Drugs in Psoriatic Arthritis
    Soriano, Enrique R.
    JOURNAL OF RHEUMATOLOGY, 2012, 39 : 67 - 70
  • [49] Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
    Stevenson, Matt
    Archer, Rachel
    Tosh, Jon
    Simpson, Emma
    Everson-Hock, Emma
    Stevens, John
    Hernandez-Alava, Monica
    Paisley, Suzy
    Dickinson, Kath
    Scott, David
    Young, Adam
    Wailoo, Allan
    HEALTH TECHNOLOGY ASSESSMENT, 2016, 20 (35) : 1 - +